{"id":118035,"date":"2021-06-24T11:00:00","date_gmt":"2021-06-24T11:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=28844972884497"},"modified":"2021-06-24T11:00:00","modified_gmt":"2021-06-24T11:00:00","slug":"sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/","title":{"rendered":"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma"},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><span style=\"font-weight: 400;\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Sialorrhea-Pipeline-Insights.jpg?1624527514288\" alt=\"Sialorrhea-Pipeline-Insights\" width=\"650\" height=\"282\" \/><\/span><\/p>\n<p>\u00a0<\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight\u2019s <\/span><strong>Sialorrhea Pipeline Insights<\/strong><span style=\"font-weight: 400;\"> report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Sialorrhea domain.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>Sialorrhea Pipeline Analysis<\/strong><\/a><span style=\"font-weight: 400;\"> report offers a complete analysis of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for Sialorrhea emerging therapies.\u00a0<\/span>The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.<\/p>\n<p><strong>Some of the key highlights from the <a href=\"https:\/\/www.delveinsight.com\/report-store\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\">Sialorrhea Pipeline<\/a> report:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">At present, the treatment option for Sialorrhea includes a conservative approach (such as observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy. Pharmacotherapy includes both prescribed and off-label medication.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Myobloc is the first and only approved botulinum toxin type B for the treatment of cervical dystonia and chronic sialorrhea.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Currently, some of the key pharmaceutical companies at the global level such as <\/span><strong>Orient Pharma,\u00a0 Nobelpharma, Aytu BioPharma,<\/strong><span style=\"font-weight: 400;\"> and many others are involved in the development of <\/span><strong>therapies for Sialorrhea<\/strong><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Some of the <\/span><strong>key therapies in the Sialorrhea Pipeline<\/strong><span style=\"font-weight: 400;\"> include <\/span><strong>OC oral solution, NPC-22, NT0502, and others. <\/strong><span style=\"font-weight: 400;\">The launch of the therapies is expected to fuel the <\/span><strong>Sialorrhea market growth<\/strong><span style=\"font-weight: 400;\"> in the coming years.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The off-label drugs in the Sialorrhea market are likely to observe a sharp decline in the coming years owing to the arrival of approved products. Since the majority of the Sialorrhea pipeline therapies are in the initial phase of development, the change in the therapeutics landscape is likely to take a few years.<\/span><\/li>\n<\/ul>\n<p>Request for Sample @<strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\">Sialorrhea Pipeline Insights and Outlook<\/a><\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>Sialorrhea Pipeline Analysis<\/strong><\/a><strong>: Drug Profile\u00a0<\/strong><\/p>\n<ul>\n<li><strong>NT0502: <span style=\"font-weight: 400;\">NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation as a result of limitations in a person\u2019s ability to control and swallow oral secretions.<\/span><\/strong><\/li>\n<li><strong>NPC-22: <span style=\"font-weight: 400;\">Nobelpharma is developing NPC-22 for the treatment of hypersalivation in partnership with Kitasato University. The vaccine is currently in the Phase I stage of development.\u00a0\u00a0<\/span><\/strong><\/li>\n<li><strong>OC oral solution: <span style=\"font-weight: 400;\">Orient Pharma is working on OC oral solution. OC Oral solution is developed as a new treatment option that can be used to titrate saliva secretion rates to a level that is low enough to prevent unintentional loss (i.e. drooling) but not so low as to cause an uncomfortably dry mouth.<\/span><\/strong><\/li>\n<\/ul>\n<p>Dive deeper to know more @<strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\">Sialorrhea therapeutics and drugs pipeline<\/a><\/strong><\/p>\n<p><strong>Key Pipeline Therapies along with Companies\u00a0<\/strong><\/p>\n<ul>\n<li><strong>OC oral solution: Orient Pharma<\/strong><\/li>\n<li><strong>NPC-22: Nobelpharma<\/strong><\/li>\n<li><strong>NT0502: Aytu BioPharma<\/strong><\/li>\n<\/ul>\n<p>And many others.<\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>Sialorrhea Pipeline Therapeutics Assessment<\/strong><\/a><\/p>\n<ul style=\"list-style-type: circle;\">\n<li><strong>By Product Type<\/strong>\n<ul style=\"list-style-type: square;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Monotherapy<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Combination Therapy\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Mono\/Combination.<\/span><\/li>\n<\/ul>\n<\/li>\n<li><strong>By Stage<\/strong>\n<ul style=\"list-style-type: disc;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Discovery\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pre-clinical<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase I<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase II<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase III<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pre-registration\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li><strong>By Route of Administration<\/strong>\n<ul style=\"list-style-type: square;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Oral<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Parenteral<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Intravenous<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Subcutaneous<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Topical<\/span><\/li>\n<\/ul>\n<\/li>\n<li><strong>By Molecule Type<\/strong>\n<ul style=\"list-style-type: square;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Monoclonal Antibody<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Peptides<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Polymer<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Small molecule<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Gene therapy<\/span><\/li>\n<\/ul>\n<\/li>\n<li><strong>Targets:<\/strong>\n<ul style=\"list-style-type: square;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Protease<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Immunomodulatory<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Multiple Kinase Inhibitor<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul style=\"list-style-type: circle;\">\n<li><strong>By Mechanism of Action<\/strong>\n<ul style=\"list-style-type: square;\">\n<li>Alpha 2 adrenergic receptor agonists<\/li>\n<li>Muscarinic receptor antagonists<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Got queries? Reach out for more information @ <a href=\"https:\/\/www.delveinsight.com\/report-store\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>Sialorrhea Drug Pipeline Assessment<\/strong><\/a><strong>\u00a0<\/strong><\/p>\n<p><strong>Scope of the Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Coverage: <\/strong><span style=\"font-weight: 400;\">Global<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Key Market Players: <\/strong><span style=\"font-weight: 400;\">Orient Pharma, Nobelpharma, Neos Therapeutics, Aytu BioPharma, and many others.<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Key Pipeline Therapies: <\/strong><span style=\"font-weight: 400;\">OC oral solution, NPC-22, NT0502, and many others.\u00a0<\/span><\/li>\n<\/ul>\n<p><strong>Table of Content\u00a0<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Report Introduction<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">2<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea\u00a0<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">3<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Current Treatment Patterns<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">4<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea \u2013 DelveInsight\u2019s Analytical Perspective<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">5<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Therapeutic Assessment<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">6<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Late Stage Products (Phase-III)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">7<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Mid Stage Products (Phase-II)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">8<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Early Stage Sialorrhea Products (Phase-I)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">9<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Pre-clinical Products and Discovery Stage Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">10<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Inactive Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">11<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Dormant Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">12<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Discontinued Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">13<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Product Profiles<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">14<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Key Companies<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">15<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Key Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">16<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Dormant and Discontinued Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">17<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Unmet Needs<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">18<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Future Perspectives<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">19<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Sialorrhea Analyst Review<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">20<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Appendix<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">21<\/span><\/td>\n<td><span style=\"font-weight: 400;\"> Report Methodology<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Know more of what\u2019s covered in the\u00a0<strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\">Sialorrhea Pipeline Assessment<\/a>\u00a0<\/strong>report<\/p>\n<p><strong>Key Questions Answered in the Sialorrhea Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the current options for Sialorrhea treatment?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many companies are developing therapies for the treatment of Sialorrhea?\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the principal therapies developed by these companies in the industry?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many therapies are developed by each company for the treatment of Sialorrhea?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many Sialorrhea emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Sialorrhea?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Sialorrhea market?\u00a0<\/span><\/li>\n<\/ul>\n<p>Request for a Webex demo @<strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/sialorrhea-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\">Sialorrhea Drug Pipeline<\/a><\/strong> and get a walk-through of our report<\/p>\n<p><strong>Related Reports<br \/>\n<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/sialorrhea-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>Sialorrhea Market Insight<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cSialorrhea Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Sialorrhea market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/sialorrhea-epidemiology-forecast?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>Sialorrhea Epidemiology Forecast<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cSialorrhea Epidemiology Forecast 2030\u201d report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Sialorrhea in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/emphysema-market\"><strong>Emphysema Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cEmphysema Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Emphysema market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/h3n2-infection-market\"><strong>H3N2 Infection Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cH3N2 Infection Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the H3N2 Infection market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/lennox-gastaut-syndrome-market\"><strong>Lennox Gastaut Syndrome Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cLennox Gastaut Syndrome Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lennox Gastaut Syndrome market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market\"><strong>Ulcerative Colitis (UC) Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cUlcerative Colitis (UC) Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Ulcerative Colitis (UC) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-market\"><strong>Global Messenger RNA Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u2018Global Messenger RNA (mRNA) based Vaccines and Therapeutics Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of the mRNA-based Vaccines and Therapeutics, along with its historical and forecasted epidemiology and market trends in North America, Europe, Asia, and ROW (rest of the world).<\/span><\/p>\n<p><strong>Healthcare Blogs By DelveInsight<\/strong><\/p>\n<ul>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/age-related-hearing-loss-device-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Age-Related Hearing Loss Devices Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/eye-disorders-treatment-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Eye Disorders Prevalence and Key Companies<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/medical-device-2021\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Upcoming Devices in Medtech Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/presbyopia-treatment-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Key Companies in the Presbyopia Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/spinal-stenosis-devices-market-size\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Medical devices for Spinal Stenosis Treatment<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/spinal-stenosis-devices-market-size\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Spinal Stenosis Devices Key Companies<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/adult-onset-stills-disease-treatment-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Adult-Onset Still\u2019s Disease Market Trends<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/bone-cancer-treatment-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Key Companies in Bone Cancer Market\u00a0<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/elastomeric-pump-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Elastomeric Pump Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/endoscopy-fluid-management-systems-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Key Companies in the Endoscopy Fluid Management Systems Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/migraine-types-risk-factors-symptoms-and-treatment-options\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Migraines Therapeutics Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/pacemakers-pipeline-landscape\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Pacemakers Pipeline Key Companies<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Clinical Development of Aducanumab<\/a><\/strong><\/li>\n<\/ul>\n<p>\u00a0<\/p>\n<p><strong>About <\/strong><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>DelveInsight<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.\u00a0 Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform <\/span><a href=\"https:\/\/www.delveinsight.com\/pharmdelve?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>PharmDelve<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><strong>Connect With Us at <\/strong><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\"><strong>LinkedIn<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\"><strong> Facebook<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\"><strong> Twitter<\/strong><\/a><\/p>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Shruti Thakur<br \/> +1(919)321-6187<br \/> info@delveinsight.com<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\">Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; DelveInsight&rsquo;s Sialorrhea Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Sialorrhea domain. The Sialorrhea Pipeline Analysis report offers a complete analysis of the therapeutics landscape by [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\">Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-118035","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma - Business\" \/>\n<meta property=\"og:description\" content=\"&nbsp; DelveInsight&rsquo;s Sialorrhea Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Sialorrhea domain. The Sialorrhea Pipeline Analysis report offers a complete analysis of the therapeutics landscape by [&hellip;] The post Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-24T11:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\",\"name\":\"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"datePublished\":\"2021-06-24T11:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/","og_locale":"en_US","og_type":"article","og_title":"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma - Business","og_description":"&nbsp; DelveInsight&rsquo;s Sialorrhea Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Sialorrhea domain. The Sialorrhea Pipeline Analysis report offers a complete analysis of the therapeutics landscape by [&hellip;] The post Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/","og_site_name":"Business","article_published_time":"2021-06-24T11:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/","url":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/","name":"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","datePublished":"2021-06-24T11:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2021\/06\/24\/sialorrhea-therapeutics-landscape-anticipated-to-transform-with-the-approval-of-pipeline-therapies-by-key-players-including-orient-pharma-nobelpharma-and-aytu-biopharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/118035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=118035"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/118035\/revisions"}],"predecessor-version":[{"id":118036,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/118035\/revisions\/118036"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=118035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=118035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=118035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}